Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation

Lehrnbecher, Thomas; Bochennek, Konrad; Groll, Andreas H.

doi:10.3390/jof9030387

Open AccessReview

Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation

by

Thomas Lehrnbecher

^1,*

,

Konrad Bochennek

¹

and

Andreas H. Groll

²

¹

Division of Pediatric Hematology and Oncology, Hospital for Children and Adolescents, University Hospital, Johann Wolfgang Goethe University, 60589 Frankfurt am Main, Germany

²

Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology/Oncology, University Children’s Hospital, 48149 Muenster, Germany

^*

Author to whom correspondence should be addressed.

J. Fungi 2023, 9(3), 387; https://doi.org/10.3390/jof9030387

Submission received: 2 March 2023 / Revised: 18 March 2023 / Accepted: 21 March 2023 / Published: 22 March 2023

(This article belongs to the Special Issue Pediatric Fungal Infections)

Download

Browse Figure

Review Reports Versions Notes

Abstract

Invasive fungal diseases (IFDs), in particular invasive mold infections, still pose considerable problems in the care of children and adolescents treated for cancer or undergoing hematopoietic cell transplantation. As these infections are difficult to diagnose, and the outcomes for IFDs are still unsatisfactory, antifungal prophylaxis has become an important strategy in the clinical setting. Antifungal prophylaxis is indicated in patients at high risk for IFD, which is commonly defined as a natural incidence of at least 10%. As there is a growing interest in pediatric-specific clinical trials and pediatric-specific guidelines, this review focuses on the available data of mold-active antifungal prophylaxis in children and adolescents. The data demonstrate that a major effort is needed to characterize the pediatric patient population in which the net effect of prophylactic antifungals will be beneficial as well as to find the optimal prophylactic antifungal compound and dosage.

Keywords: child; cancer; invasive fungal disease; prophylaxis

Share and Cite

MDPI and ACS Style

Lehrnbecher, T.; Bochennek, K.; Groll, A.H. Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation. J. Fungi 2023, 9, 387. https://doi.org/10.3390/jof9030387

AMA Style

Lehrnbecher T, Bochennek K, Groll AH. Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation. Journal of Fungi. 2023; 9(3):387. https://doi.org/10.3390/jof9030387

Chicago/Turabian Style

Lehrnbecher, Thomas, Konrad Bochennek, and Andreas H. Groll. 2023. "Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation" Journal of Fungi 9, no. 3: 387. https://doi.org/10.3390/jof9030387

APA Style

Lehrnbecher, T., Bochennek, K., & Groll, A. H. (2023). Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation. Journal of Fungi, 9(3), 387. https://doi.org/10.3390/jof9030387

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI